CancerNetwork Members: Login | Register
CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » CONFERENCES » AACR 2012

CONFERENCE REPORT 

Hypofractionated Stereotactic Radiotherapy to Surgical Cavity After Resection for Brain Metastasis

2012 Annual Meeting of the American Association for Cancer Research

By Michael Kaufman | April 5, 2012

Hypofractionated stereotactic radiotherapy (SRT) appears to be safe and effective in preventing recurrence at resection cavities following surgical resection of brain metastasis and may spare many patients from whole brain radiotherapy (WBRT) and its adverse effects, according to Hsiang-Hsuan M. Yu, MD, of the Moffitt Cancer Center in Tampa, Florida (AACR abstract 737).

MRI of brain. (Top left) Initial MRI shows a tumor in the right and left frontal lobe as well as the right thalamus. (Top right) MRI after surgery, radiation, and chemotherapy. The tumor has completely disappeared except for slight enhancement adjacent to the surgical margin. (Bottom left) Increase in size of the thalamic tumor two months after stereotactic radiotherapy. (Bottom right) After 6 cycles of TMZ therapy, the thalamic lesion enlarged, and the patient developed dysarthria and hemiparesis. Source: Fujimaki T, Ishii H, Matsuno A, Arai H, Nakagomi T. Effectiveness of interferon-beta and temozolomide(Drug information on temozolomide) combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma.World J Surg Oncol. 2007 Aug 4;5:89.

To investigate the efficacy of postoperative hypofractionated SRT after resection of brain metastasis, investigators retrospectively analyzed 52 consecutive patients with brain metastasis from solid tumors who underwent surgical resection followed by SRT to the resection cavity for at least 1 metastasis.

(MORE: 'Striking' Results Seen in Phase II Trial of Selumetinib in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum)

A total of 25 to 30 Gy in 5 daily fractions over a 1-week period was prescribed to the resection cavity with a margin of 2 mm expansion (median dose 28.5 Gy) between 2 to 4 weeks postoperatively.

Synchronous oligometastasis, if present, was treated with radiosurgery. No patients received upfront WBRT. All patients were followed up for at least 6 months. The radiographic end point was local tumor control at resection cavity.

Preliminary analyses showed a local control rate of 86% at 12 months at the resection site; none of the patients developed radiation-induced injury at the resection site.

Although WBRT decreases the risk of recurrence at the resection site, it is also associated with neurocognitive complications. Postoperative radiosurgery is a new technique aimed at decreasing recurrence and sparing patients from WBRT, but a single high-dose fraction may increase radiation-induced necrosis.

“Hypofractionated SRT delivers a higher radiobiological dose which may potentially provide higher local tumor control, and fractionation may lower risk of radiation-induced injury,” explained Dr. Yu.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.

Presentations Reflect Theme of 2012 AACR Meeting, ‘Accelerating Science: Concept to Clinic’

Photoacoustic Tomography: Ultrasonically Breaking Through the Optical Diffusion Limit

Development of a Novel Therapeutic Agent for Breast Cancer Based on a New Pathway Analysis of Triple-Negative Breast Cancer

Hypofractionated Stereotactic Radiotherapy to Surgical Cavity After Resection for Brain Metastasis

Cytokine Signaling Through JAK2/STAT3 Pathway is a Viable Therapeutic Target in NSCLC

'Striking' Results Seen in Phase II Trial of Selumetinib in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum






 
AACR 2012 COVERAGE

Inotuzumab Ozogamicin Achieves ‘Markedly Long’ Antitumor Response in Indolent B-Cell NHL
April 5, 2012
NIH Research Funding Faces ‘Unprecedented Threat’
April 5, 2012
Hypofractionated Stereotactic Radiotherapy to Surgical Cavity After Resection for Brain Metastasis
April 5, 2012
Development of a Novel Therapeutic Agent for Breast Cancer Based on a New Pathway Analysis of Triple-Negative Breast Cancer
April 5, 2012
'Striking' Results Seen in Phase II Trial of Selumetinib in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum
April 5, 2012
 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Skin Lesions
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Colorectal Lesions
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter



CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy